5 Best Growth Stocks Under $25

4. TG Therapeutics, Inc. (NASDAQ:TGTX)

P/E Ratio: 74.07
Latest Share Price: $17.08
Number of Hedge Fund Holders: 28

TG Therapeutics, Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company that acquires, develops, and commercializes novel treatments for various conditions. TG Therapeutics, Inc. (NASDAQ:TGTX)’s lead product is BRIUMVI, an anti-CD20 monoclonal antibody for treating adult patients with relapsing forms of multiple sclerosis.

TG Therapeutics, Inc. (NASDAQ:TGTX) stock exploded in 2023, rallying 44% as the team continues to execute well and progress on corporate goals. The company delivered a net solid quarterly revenue of $166 million, exceeding expectations.

Out of the 910 hedge funds tracked by Insider Monkey, 28 hedge funds reported owning a stake in TG Therapeutics, Inc. (NASDAQ:TGTX). The biggest stakeholder of TG Therapeutics, Inc. (NASDAQ:TGTX) during this period was Guy Levy’s Soleus Capital which owns $24.11 million stake in TG Therapeutics, Inc. (NASDAQ:TGTX).

Follow Tg Therapeutics Inc. (NASDAQ:TGTX)

[/company-follow-email]